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During inflammation, activated monocytes (Mo) migrate
into tissues where they interact with extracellular matrix
components such as hyaluronate (HA), produced in high
amounts at inflammatory sites. We determined whether
Mo that had invaded sites of cutaneous inflammation
bind HA and express the putative HA receptors CD44
isoforms, ICAM-1, or receptor for hyaluronate-mediated
motility (RHAMM). In cutaneous inflammation, activ-
ated infiltrating Mo displayed high HA avidity and
expressed epitopes encoded by CD44s, CD44 variant
exons v3, v4, v5, v6, v7, and v9, and ICAM-1, but not
RHAMM. We further investigated how activation affects
the avidity of Mo for HA and which receptors were
responsible for such binding. Mo freshly purified from
human peripheral blood bound little HA and expressed
CD44s but no epitopes encoded by CD44v exons,
ICAM-1, or RHAMM. During short-term tissue culture,
Early during an inflammatory response in skin, monocytes(Mo) pass from the circulation into the extracellular matrix(ECM)-rich dermis. Hyaluronate (HA) is a major compon-ent of the ECM, and its concentration is strongly elevatedat inflammatory sites, e.g., in allergic contact dermatitis
(ACD) (Campbel et al, 1982a; Lesley et al, 1993a; Sherman et al, 1994;
Tammi et al, 1994). The glycosaminoglycan HA is thought to promote
migration of cells that carry appropriate receptors (Thomas et al, 1992;
Noble et al, 1993; Turley et al, 1994; Savani et al, 1995). To date, three
cellular HA receptors have been identified on immunocompetent cells:
CD44 (Aruffo et al, 1990), ICAM-1 (McCourt et al, 1994), and receptor
for hyaluronate-mediated motility (RHAMM) (Hardwick et al, 1992;
Masellis-Smith et al, 1996).
The CD44 cell surface molecules are expressed on a wide variety of
human lymphoid and nonlymphoid cells (Lesley and Hyman, 1992;
Herrlich et al, 1993; Hudson et al, 1995). The CD44 molecules are
encoded by one gene composed of a total of 20 exons, the five most 59
of which form the N-terminal extracellular region (Screaton et al, 1992).
The following 10 variant exons encode sequences that can be spliced out
or inserted in various linear combinations into the extracellular portion
Manuscript received August 12, 1997; revised March 31, 1998; accepted for
publication April 27, 1998.
Reprint requests to: Dr. Johannes M. Weiss, Department of Dermatology,
University of Freiburg, Hauptstrasse 7, D-79104 Freiburg, Germany.
Abbreviations: ACD, allergic contact dermatitis; cMFI, corrected mean
fluorescence intensity; HA, hyaluronate; MFI, mean fluorescence intensity; Mo,
monocytes.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
227
Mo upregulated their HA avidity and expression of
ICAM-1, CD44s, and epitopes encoded by CD44v, all of
which were further augmented by IFN-g or lipopoly-
saccharide, whereas RHAMM was not detectable. Thus
in vitro activated Mo resembled Mo that had migrated to
inflammatory sites in vivo. Lipolysaccharide or IFN-g-
induced HA binding was inhibited by more than 90%
with monoclonal antibodies directed against N-terminal
HA binding domains of CD44s, but not by monoclonal
antibodies against CD44v epitopes or ICAM-1. In conclu-
sion, we show that upon in vitro or in vivo activation, Mo
enhance their capacity to bind HA. This is critically
dependent upon the expression of CD44s epitopes. Regu-
lated CD44–HA interactions may be important for the
ability of Mo to migrate into and within sites of inflam-
mation and for Mo effector functions. Key words: CD44/
ICAM-1/macrophages/RHAMM. J Invest Dermatol 111:227–
232, 1998
behind the exon 5 sequence of CD44. The common N-terminal five
exon sequences carry two HA-binding motifs (Sy et al, 1991; Peach et al,
1993). Binding of CD44 to HA is modulated by either post-translational
modifications such as phosphorylation, palmitoylation, or O-and N-
linked glycosylation, or the presence of variant exon sequences in the
molecule (Sy et al, 1991; Camp et al, 1991; Lesley et al, 1993a,b; Perschl
et al, 1995; Uff et al, 1995; Pure et al, 1995; Sleeman et al, 1996).
RHAMM was described as the HA-binding protein of the cell surface
hyaluronate receptor complex (Hardwick et al, 1992). Three RHAMM
proteins were detected in a human breast carcinoma cell line that are
probably the result of alternative splicing or post-translational modifica-
tion (Wang et al, 1996). RHAMM promotes lymphocyte and tumor cell
locomotion by HA interaction (Hardwick et al, 1992; Samuel et al, 1993;
Turley et al, 1993). Recently a third functional HA receptor has been
identified on rat liver endothelial cells as ICAM-1 (McCourt et al, 1994).
In vitro culture of human peripheral blood monocytes and alveolar
macrophages was previously demonstrated to upregulate variant CD44
isoform expression and induce their HA-binding capacity (Camp et al,
1991; Culty et al, 1994; Levesque and Haynes, 1996). We expanded these
studies by demonstrating that in vitro and in vivo activation by IFN-γ or
lipolysaccharide (LPS) stimulates the capacity of Mo to bind HA and that
distinct CD44 isoforms but not ICAM-1 or RHAMM are the principal
HA receptors on activated Mo. Furthermore, Mo infiltrating inflam-
matory sites in vivo, i.e., during allergic contact dermatitis, express CD44
isoforms and bind HA.
MATERIALS AND METHODS
Media and reagents Complete-RPMI 1640 (c-RPMI) (Gibco, Eggenstein,
Germany) was supplemented with 10% heat inactivated fetal calf serum
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(Gibco), 25 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid (Sigma,
Mu¨nchen, Germany), 1 mM nonessential amino acids (Gibco), 2 mM L-
glutamine (Gibco), 45 µg penicillin, and 45 µg streptomycin (Gibco). IFN-γ
was procured from Genzyme (Cambridge, MA) and LPS (from Escherichia
coli serotype 0111:B4) from Sigma. Hyaluronidase (Calbiochem, Frankfurt,
Germany) and heparinase III (Sigma) were used at a concentration of 10 U per
ml or 0.3 U per ml, respectively. HA was bought from Sigma and conjugated
to fluoroscein isothiocyanate (FITC; Sigma) by the method of DeBelder and
Wik (1975).
Monoclonal antibodies (MoAb) and anti-sera MoAb Leu44 (anti-pan
CD44, clone L178, mouse IgG1), Leu4 (anti-CD3, clone SK7, mouse IgG1),
and IgG2b control MoAb were obtained from Becton Dickinson (Heidelberg,
Germany), and unconjugated and cy3-conjugated RMO52 (anti-CD14, mouse
IgG2a) and IgG1 control MoAb were obtained from Dianova (Hamburg,
Germany). SFF2 (anti panCD44, mouse IgG1), VFF23 (anti-CD44v3, mouse
IgG1), VFF8 (anti-CD44v5, mouse IgG1), VFF18 (anti-CD44v6, mouse IgG1),
VFF9 (anti-CD44v7, mouse IgG1), and VFF16 (anti-CD44v10, mouse IgG1)
were a kind gift of Dr. Adolf (Bender, Vienna, Austria). MoAb 11.9 (anti-
CD44v6, mouse IgG1), 11.10 (anti-CD44v4, mouse IgG1), and 11.24 (anti-
CD44v9, mouse IgG1) were obtained from ECACC (Porton Down, U.K.)
(Mackay et al, 1994) and 48H10 (anti-ICAM-1, mouse IgG1) was obtained
from Immunotech (Hamburg, Germany). RR1 (anti-ICAM-1, mouse IgG1)
was a kind gift of Dr. T.A. Springer (Department of Pathology, Harvard Medical
School, Boston, MA). MoAb MEM-85 (pan CD44, mouse IgG1) was procured
from Monosan (Uden, The Netherlands) and 3G5 (anti-CD44v3, mouse IgG1)
was from R&D Systems (Abingdon, U.K.). Two different RHAMM polyclonal
rabbit anti-sera were used: R3.8 was kindly provided by Dr. E. Turley (Manitoba
Institute of Cell Biology, Winnipeg, Canada), and a second RHAMM anti-
serum was provided by V. Assmann (Assmann et al, 1998; Hofmann et al, 1998).
Hermes-1 and Hermes-3 (both pan CD44, mouse IgG1) were a gift of Dr. S.
Jalkanen (University of Turku, Finland). DTAF-conjugated goat F(ab)2 anti-
mouse IgG (H 1 L) MoAb and DTAF-conjugated goat-F(ab)2 anti-rabbit IgG
(H 1 L) were obtained from Dianova.
Isolation and activation of monocytes PBMC were isolated by density
centrifugation of buffy coats (Lymphoprep 1077, Sigma), obtained from healthy
donors. PBMC were counted, viability determined by trypan blue dye exclusion
(.95%) and cells resuspended in supplemented-RPMI at a concentration of
5 3 106 cells per ml. Aliquots were dispensed into plastic Petri dishes (Greiner)
and cultured 0–96 h. Monocytes were enriched to a purity of 90–95% by
plastic adherence (Culty et al, 1994), or purified by microbead positive separation
to a purity of 95–98% (MACS, Miltenyi Biotec, Bergisch Galdbach, Germany)
with MoAb RMO52 and goat anti-mouse IgG1 coupled to microbeads (Miltenyi
Biotec) as described (Simon et al, 1995). IFN-γ (250 U per ml) or LPS (5 µg
per ml) were added for the entire culture period. Monocytes were harvested
with 0.5 mM ethylenediamine tetraacetic acid in phosphate buffered saline,
washed extensively, and then analyzed by fluorescence-activated cell sorter
(FACS) analysis, western blotting, or northern blotting.
Flow cytometry Experiments were performed by using modifications of
previously described methods (Weiss et al, 1995). Briefly, for three color FACS
analysis Mo where stained in phosphate buffered saline (4°C) with unlabeled
primary MoAb, DTAF-labeled goat anti-mouse (Fab)2 (H 1 L) MoAb
(Dianova), followed by a 10 min incubation step in 2% normal murine serum,
and subsequently stained with CD14 PE labeled MoAb or PE-labeled IgG2a
control MoAb. 7-Aminoactinomycin D (2.5 µg per ml, Sigma) was added to
exclude nonviable cells by life gating. For HA-FITC binding experiments, cells
were incubated at 4°C for 30 min in phosphate buffered saline containing
100 µg HA-FITC per ml, followed by extensive washing. Unlabeled HA
(100 µg per ml) served as control. To test hyaluronidase sensitivity of Mo-HA-
FITC binding, cells were treated either prior or following HA-FITC labeling
with hyaluronidase (10 U per ml, 30 min, 4°C) or heparinase III (0.3 U per
ml, 30min, 4°C). MoAb blocking of HA-FITC binding was performed by
pretreating cell suspensions for 15 min with the indicated MoAb (10 µg per
ml, 4°C), followed by addition of HA-FITC (100 µg per ml) for 30 min, 4°C.
Cell suspensions were analyzed by FACScan, using FACScan research software
(Becton Dickinson) to assess 104 CD141 or CD31 viable cells. Mean fluores-
cence intensity (MFI) was calculated with the FACScan research software (Becton
Dickinson). Corrected mean fluorescence intensity (cMFI) was calculated by
subtraction of MFI of cells stained with control MoAb or unlabeled HA and
secondary FITC-labeled MoAb from MFI of cells stained with specific MoAb
or HA-FITC. For intracellular detection of RHAMM, cells were permeabilized
with Fix and Perm (Dianova, Hamburg, Germany) according to the supplier’s
protocol.
Northern blot analysis For northern blot analysis enriched Mo (.90%)
were used either fresh or cultured for 48 h in the presence or absence of
IFN-γ as described above. Total cellular RNA was extracted from Mo using
guanidinium isothiocyanate-containing lysis buffer with subsequent CsCl-
gradient purification as described (Simon et al, 1996). Five micrograms of total
cellular RNA were size-fractionated on 1% formaldehyde agarose gels and
transferred onto Hybond nylon N-plus membranes (Amersham, Braunschweig,
Germany) in 103sodium citrate/chloride buffer and UV cross-linked. For blot
hybridization a 810 bp human cDNA probe containing exons 1–5, 15–16 of
the invariant extracellular domain of the CD44 molecule was 32P-labeled by
random primer method as described earlier (Hofmann et al, 1991). After
washing, blots were exposed to film for autoradiography. Control hybridizations
with a human β-actin probe (Hofmann et al, 1991) were performed after blots
were stripped in 0.13sodium citrate/chloride buffer/1% sodium dodecyl sulfate
for 1 h at 90°C.
Western blot analysis Freshly isolated or cultured Mo were lysed in a buffer
containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% DOC
(sodiumdeoxycholate), 0.1% sodium dodecyl sulfate, and 2 mM phenylmethyl-
sulfonyl fluoride. After DNA shearing, a soluble protein extract was prepared
by centrifugation at 10,000 3 g (15 min, 4°C). For each sample, 15 µg protein
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(10% polyacrylamide gel) and electrically transferred to nitrocellulose filters
(Schleicher & Schuell, Dassel, Germany). CD44 protein on nitrocellulose filters
was detected using the CD44 MoAb Hermes-3 and indirect immunoperoxidase
staining with a HRP-conjugated F(ab)2 fragment of goat anti-mouse IgG
(Dianova). Protein bands were visualized using the enhanced chemiluminescence
detection system (Amersham, Braunschweig, Germany).
Immunohistochemistry Previously described methods were applied for
immunohistochemical double staining (Simon et al, 1994). Biopsies were taken
from the lesional and nonlesional skin of patients with allergic contact dermatitis
following informed consent. In brief, sections were incubated with MoAb
against CD44 isoforms and ICAM-1 (Leu44, MEM-85, VFF8, VFF18, VFF17,
11.24, 48H10), for 30 min at room temperature, followed by a FITC-conjugated
goat-F(ab)2-anti-mouse IgG (H 1 L)-antibody (30 min, room temperature).
Alternatively, sections were incubated with HA-FITC (100 µg per ml) for
30 min at room temperature. In a second step, sections were overlaid
with Cy3-conjugated-anti-CD14 or -anti-CD3 MoAb for 30 min (room
temperature). Staining was evaluated with a Zeiss Axioskop (Go¨ttingen,
Germany), equipped with a MC100 camera system.
RESULTS
In vivo HA binding and HA-receptor expression on Mo infiltrat-
ing inflammatory sites Because sites of cutaneous inflammation
are rich in HA and cells migrating into these sites likely require affinity
for HA, we examined the HA-binding properties of Mo infiltrating
inflammatory sites of ACD. Cryosections of ACD were stained with
cy3-conjugated anti-CD14 to identify Mo (red color) and with HA-
FITC (green). Double-staining appears yellow. CD141 Mo sur-
rounding the subepidermal vascular plexus of inflamed skin (but not
of normal skin, data not shown) avidly bound HA-FITC (Fig 1B).
Little HA-FITC binding was detected on keratinocytes or vascular
endothelial cells in either inflamed or normal skin (Fig 1B and data
not shown). Furthermore, double-stainings of ACD sections with
cy3-conjugated CD3 MoAb and HA-FITC revealed that CD31
lymphocytes did not bind significant amounts of HA-FITC (Fig 1C).
To explore HA-receptor expression on Mo in vivo, double-staining with
cy3-conjugated MoAb against CD141 and with MoAb recognizing
N-terminal CD44 epitopes, epitopes encoded by CD44 variant exons
v3, v4, v5, v6, and v9, or ICAM-1 and RHAMM (detected with
DTAF-conjugated secondary antibody, green) were performed
(Fig 1D–L). In contrast to nonactivated Mo in normal skin (not
shown), the perivascular Mo from the inflamed site were found to
express all these epitopes (Fig 1D–L). Mo showed neither extracellular
nor intracellular staining with two different polyclonal anti-sera specific
for human RHAMM (Assmann et al, 1998; Hofmann et al, 1998, data
not shown).
Activation-dependent upregulation of HA-binding affinity on
human peripheral blood Mo Because IFN-γ and LPS have both
been reported to induce Mo activation and recruitment into inflam-
matory sites such as ACD (Becker and Knop, 1993), we compared the
HA-binding capacity of freshly purified Mo and of purified Mo
cultured in plastic dishes for 48–96 h in the presence or the absence
of IFN-γ or LPS. Freshly isolated Mo displayed only low affinity for
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Figure 1. Monocytes infiltrating at sites
of cutaneous inflammation upregulate
HA binding and HA-receptor expression.
Cryosections of skin samples from allergic
contact dermatitis were stained with the
following. (A) IgG1 control MoAb, secondary
cy3-conjugated goat anti-mouse MoAb, and
HA-FITC. (B, D–L) cy3-conjugated anti-
CD14 MoAb (red) and the indicated FITC-
labeled reagents (green). Double positive
cells appear yellow-orange (B). Arrows:
CD141 – HA-binding cells around the
subpapillary plexus. (C) cy3-conjugated anti-
CD3 MoAb (red) and HA-FITC (green).
*CD31 cells do not bind HA. (D) ICAM-1,
(E) panCD44 MoAb (SFF-2), (F) panCD44
MoAb (MEM-85), (G) CD44v3 MoAb
(VFF23), (H) CD44v4 MoAb (VFF11), (I)
CD44v5 MoAb (VFF8), (J) CD44v6 MoAb
(VFF18), (K) CD44v7 MoAb (VFF9), (L)
CD44v9 MoAb (11.24). Arrows: double
positive cells. In (E)–(L) epidermal keratino-
cytes appear green because they express CD44
epitopes. The dotted line indicates the dermo–
epidermal junction. Scale bars, (A, C–L)
12 µm, (B) 36 µm.
HA-FITC (Fig 2A). HA binding was slightly upregulated by culture
for 48 h in fetal calf serum-containing medium allowing plastic
adherence (Figs 2A, 3). Addition of IFN-γ or LPS to the culture
medium markedly increased Mo HA affinity (Figs 2A, 3). Increase in
HA-FITC binding was not due to an increase in Mo cell size as
determined by forward scatter size of Mo compared with their HA-
FITC cMFI (data not shown). HA-FITC binding was sensitive to
digestion with hyaluronidase, but not to heparinase III, demonstrating
the specificity of the binding (Fig 5). HA binding could not be induced
in sorted CD31 T cells from the same PBMC preparation (Fig 2B).
Activation-dependent expression of HA receptors on Mo Like
Mo activated in vivo, the Mo activated in vitro express CD44v exon
encoded epitopes (Fig 3). Freshly isolated Mo (time 0 h), analyzed by
FACScan, carry low levels of N-terminal CD44 epitopes and few
v-exon epitopes or ICAM-1. In vitro culture resulted in a time-
dependent upregulation of N-terminal CD44 epitopes, and those
encoded by CD44 exons v3, v4, v5, v6, and v9 (not v7) as well as of
ICAM-1. Addition of IFN-γ further increased expression of all epitopes,
whereas LPS had less of an effect (Fig 3). Northern blot analysis was
performed using a probe hybridizing to the invariant portion of CD44
(Fig 4A). IFN-γ and LPS stimulation resulted in a marked upregulation
of three major 1.6 kb, 2.2 kb, and 4.6 kb CD44 transcripts. In western
blot analysis using MoAb Hermes-3, unstimulated Mo were found to
express predominantly the 85 kDa form of CD44 containing no
variably spliced exons (Hofmann et al, 1991) (Fig 4B). After 72 h of
tissue culture, larger isoforms of µ160 and 190 kDa appeared (Fig 4B).
On the basis of our FACS experiments these larger isoforms most
likely contain protein sequences encoded by at least some of the variant
exons v3–v9. Expression of all CD44 isoforms was augmented by
IFN-γ and LPS (Fig 4B, lanes 3, 4).
Determination of RHAMM expression on the cell surface or within
the cytoplasm using two different polyclonal anti-sera for FACS analysis
(shown to detect RHAMM in different human cancer cells; Assmann
et al, 1998; Hofmann et al, 1998), revealed no immunoreactivity in
freshly isolated, tissue cultured, or IFN-γ, LPS stimulated human Mo
(Fig 3). Thus, in vitro activated Mo resemble Mo infiltrating sites
of inflammation, i.e., in ACD, with regard to their HA-receptor
expression.
CD44 is the principal HA receptor on activated Mo Because
activation-dependent induction of Mo HA affinity correlated with an
augmented surface expression of different CD44 epitopes and ICAM-1
but not RHAMM, we investigated which of these proteins were
involved in HA-FITC binding to Mo treated with IFN-γ (Fig 5). In
blocking experiments, such HA-FITC binding was sensitive to digestion
with hyaluronidase, but not to heparinase III (the latter used at a
concentration that cleaves bFGF from CD44v3, J.C. Simon, unpub-
lished results), demonstrating the specificity of the binding (Fig 5).
Importantly, HA-FITC binding could be blocked by the MoAb MEM-
85 and Hermes-1, which have been reported to interfere with the HA
avidity of N-terminal HA-binding domains in the invariant portion of
CD44 (Lesley et al, 1990; Spring et al, 1995) (Fig 5); however,
MoAb recognizing other N-terminal CD44 epitopes (Leu44, SFF2) or
CD44v3, v4, v5, v6, and v9 did not affect CD44-HA avidity (Fig 5),
indicating that although expressed by activated Mo these CD44 epitopes
do not affect their HA-binding capacity. ICAM-1 has previously been
described as an HA cell surface receptor on liver endothelial cells
(McCourt et al, 1994). Blocking with two different ICAM-1 MoAb
(48H10, RR1) did not influence HA-FITC binding of Mo stimulated
for 48 h with IFN-γ (Fig 5).
Upon stimulation, Mo upregulate expression of CD44 isoforms
encoded by exon v3 (Fig 3), which are known to be modified by
heparane sulfate (Bennett et al, 1995). To test whether such expression
of heparane sulfate modified CD44 isoforms is involved in the increased
HA affinity, Mo activated by plastic adherence, IFN-γ, or LPS
stimulation were pretreated with heparinase III and hyaluronidase as
control. Enzymatic removal of heparane sulfate from the surface of
resting or activated Mo did not modulate their HA affinity. Particularly,
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Figure 2. Activation by plastic adhesion, IFN-g, and LPS upregulates
monocyte HA-binding capacity. Purified monocytes (A) were analyzed
either fresh or following stimulation with IFN-γ or LPS for 48 h and stained
with HA-FITC (FL-1). Binding of HA to CD31 lymphocytes sorted from the
same PBMC preparation was performed accordingly (B). Representative results
of five independent experiments.
the increased HA binding of IFN-γ or LPS stimulated Mo was not
affected by either enzyme (Table I).
DISCUSSION
In this study, we show that in vitro activation by tissue culture, plastic
adhesion, and treatment with LPS and IFN-γ augment HA binding
on purified human peripheral blood Mo. The same stimuli upregulated
the expression of several putative HA receptors, i.e., CD44s, sequences
encoded by CD44 variant exons v3, v4, v5, v6, and v9, and of
ICAM-1 but not of RHAMM (Aruffo et al, 1990; Hardwick et al,
1992; McCourt et al, 1994). We further demonstrate that Mo HA
binding is mediated primarily by CD44, because HA binding could
be blocked almost completely by MoAb recognizing the N-terminal
HA-binding domains of CD44 but not by MoAb against other CD44
epitopes or ICAM-1. We interpret these results to mean that distinct
HA-binding domains within the N-terminal constant extracellular
portion of CD44 are of prime importance for HA binding by activated
Mo. Furthermore, we excluded that heparane sulfate modification of
CD44v3 containing epitopes is involved in CD44–HA interactions on
Mo by demonstrating that heparinase pretreatment did not alter Mo
HA affinity (Bennett et al, 1995). This is in accordance with previous
work showing that exon v3 containing CD44 isoforms transfected into
B lymphoma cells do not display enhanced HA binding affinity (Jackson
et al, 1995).
The activation of Mo goes along with increased CD44 gene
transcription, as indicated by the enhanced expression of all three major
CD44 RNA transcripts (northern blot) and by the enhanced level of
N-terminal epitopes (FACS). In addition, the splice regulation appears
to be affected. Variant exon sequences (v4, v5, v6, v7, v9) are included
in the CD44 proteins expressed after activation (western blot and
FACS). This is in accordance with previous reports: in a tumor cell
Figure 3. CD44 isoforms and ICAM-1, but not RHAMM, are
upregulated during monocyte activation. PBMC from a single donor were
used fresh or following culture in the presence or absence of IFN-γ or LPS for
48 h or 96 h. Cells were gated for CD14 expression and stained with
either HA-FITC, antibody against the N-terminal domain of CD44 (CD44s),
antibodies recognizing epitopes encoded by CD44 exons v3, v4, v5, v6, v7,
and v9, ICAM-1, or RHAMM. 7-Aminoactinomycin was added to exclude
dead cells. cMFI was calculated by subtracting MFI of control from MFI of
specifically stained cells, as detailed in Materials and Methods.
line of monocytic origin stimulated with IFN-γ and in human Mo
identified within cultured bulk PBMC, increased CD44v-exon (v4,
v6, v9) expression was detected (Culty et al, 1994; Mackay et al, 1994;
Levesque and Haynes, 1996). Here we have shown that IFN-γ and
LPS exert this effect on purified peripheral blood Mo.
The finding that HA affinity correlates with the state of Mo
activation suggests that an increased avidity for soluble and cell-bound
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Figure 4. CD44 mRNA and protein expression is upregulated during
Mo activation. Ninety-five per cent enriched Mo were used fresh or following
stimulation as indicated by plastic adherence, IFN-γ, LPS. (A) For northern
blot analysis, 5 µg of total RNA were size fractionated, transferred to nylon
N-plus membranes, followed by hybridization with a 810 bp human CD44s
probe containing the exons of the invariant extracellular domain of CD44 and
with a human β-actin probe. (B) For western blot analysis, 15 µg of total
cellular protein were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to nitrocellulose filters. CD44 protein was
detected by MoAb Hermes-3.
Figure 5. MoAb against panCD44 block HA binding on activated
monocytes. Monocytes were purified as described above, cultured in the
presence of IFN-γ for 48 h, and subsequently analyzed by FACS. Indicated
MoAb were added to cell suspensions 15 min prior to addition of HA-FITC.
To test for specificity, HA-FITC-labeled cells were incubated with hyaluronidase
or heparinase for 30 min at 4°C. Percentage inhibition was calculated by the
formula: 1 – (cMFI MoAb blocked/cMFI control). Positive percentage indicates
blocking of HA-FITC binding, negative percentage indicates increased binding.
The values shown are averaged from five experiments 6SD. Asterisks indicate
statistically significant inhibition (one way ANOVA, Dunnett’s test, p , 0.0001).
HA supports Mo effector functions upon migration into the tissues as
has previously been suggested for lymphocytes and tumor cells (Jalkanen
et al, 1990; Thomas et al, 1992 , 1993; Camp et al, 1993; Galluzzo
et al, 1995). We found that Mo migrating into inflammatory sites of
ACD, a cutaneous inflammatory response critically dependent upon
IFN-γ release (Becker and Knop, 1993), bind HA-FITC.
Interestingly in cryosection of human skin, as well as following
in vitro culture (data not shown), human keratinocytes that express
Table I. HA binding on activated Mo is not modulated by
pretreatment with heparinase or hyaluronidasea
HA-cold HA-FITC HA-FITC HA-FITC
Hyaluronidase Heparinase
Adherance 17.8b 34.9 35.4 37.0
IFN-γ 20.8 63.7 65.6 62.2
LPS 28.1 117.9 114.0 121.5
aMo were activated for 96 h as indicated, pretreated with hyaluronidase or heparinase
III, incubated with HA-FITC for 30 min, and analyzed by FACScan as described in
Materials and Methods.
bData are expressed as MFI as calculated by Cell Quest software.
high levels of CD44 isoforms did not bind exogenously added HA.
Such binding was recently reported for murine keratinocytes cultured
in the presence of epidermal growth factor and hydrocortisone (Kaya
et al, 1997). This can be explained by either a saturation of HA
receptors on human epidermal keratinocytes (Kaya et al, 1997), or a
modulation of HA affinity on murine cultured keratinocytes caused
by addition of hydrocortisone and growth factors to the culture medium.
Our experiments indicate that CD44 is the principal HA receptor
in human activated Mo. In addition to HA binding, CD44 may also
participate in signal transduction in Mo. For example, cross-linking of
CD44 molecules by MoAb induces IL-1 and TNF-α secretion (Noble
et al, 1993). Soluble HA stimulates IL-1 and TNF-α gene transcription
and IGF-1 protein synthesis, and activates an NF-kB/I-kBa autoregula-
tory mechanism (Webb et al, 1990; Noble et al, 1996). Furthermore,
low molecular weight HA fragments induce IL-12 and chemokines
on thioglycollate elicited peritoneal macrophages (Hodge-Dufour et al,
1997). For Mo effector function, CD44–HA interaction might thus
fulfil a dual role by facilitating Mo migration into the inflammatory
site, and at the same time augmenting Mo effector functions.
In conclusion we have demonstrated that human Mo upregulate
their HA-binding capacity upon in vitro activation by LPS or IFN-γ
and during migration to sites of cutaneous inflammation. This is
critically dependent on the expression of N-terminal HA-binding
domains within the constant region of CD44. In contrast, ICAM-1,
RHAMM, or CD44 variant exon encoded sequences, all of which
have been implicated to regulate HA avidity in other cell types, do
not appear to be directly involved in HA binding by activated Mo.
Based on these findings, we hypothesize that regulated CD44–HA
interactions are of importance for the migration of activated Mo into
sites of inflammation and may also stimulate Mo effector functions
within inflamed tissues.
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